Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Vatalanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 0.89 |
| ▸ | FLT1 known ✓ | P17948 | 18/20 | 0.89 |
| ▸ | PDGFRB known ✓ | P09619 | 8/20 | 0.89 |
| ▸ | KIT known ✓ | P10721 | 7/20 | 0.89 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 0.89 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.89 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.73 |
| ▸ | CIT | O14578 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | HLA-A | P04439 | 1/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.73 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.73 |
| ▸ | FRK | P42685 | 1/20 | 0.73 |
| ▸ | CDK8 | P49336 | 1/20 | 0.73 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.73 |
| ▸ | STK3 | Q13188 | 1/20 | 0.73 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.73 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.73 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.73 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vatalanib SCHEMBL19639128 | 0.94 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL675786 | 0.94 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL1685425 | 0.94 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6605579 | 0.88 | KDR (0.88) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131018 | 0.87 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131017 | 0.87 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL29350047 | 0.85 | FLT1 (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL18286 | 0.85 | FLT1 (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905598 | 0.84 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131019 | 0.84 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292335-B1 | COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II) | BAYER SCHERING PHARMA AG (DE) | 2007-05-30 | — | — | EP | claimed |
| EP-1731154-A1 | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof | Schering Aktiengesellschaft (DE) | 2006-12-13 | — | — | EP | claimed |
| US-20060275365-A1 | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-07 | — | — | US | claimed |
| EP-1586333-A2 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) | Schering Aktiengesellschaft (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20040147449-A1 | Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use (II) | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-07-29 | — | — | US | claimed |
| US-20030055006-A1 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | US | claimed |
| EP-1166798-A1 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use | Schering Aktiengesellschaft (DE) | 2002-01-02 | — | — | EP | claimed |
| EP-1166799-A1 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-02 | — | — | EP | claimed |
| US-20120288497-A1 | COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLT1 ANTAGONIST FOR TREATING CANCER | MEDIMMUNE LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| EP-1292335-B1 | COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II) | BAYER SCHERING PHARMA AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| US-20070059359-A1 | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| EP-1731153-A1 | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl| and salts thereof | Schering Aktiengesellschaft (DE) | 2006-12-13 | — | — | EP | disclosed |
| EP-1731154-A1 | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof | Schering Aktiengesellschaft (DE) | 2006-12-13 | — | — | EP | disclosed |
| US-20060275365-A1 | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-07 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| US-20030055006-A1 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | US | disclosed |
| EP-1292335-A2 | COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II) | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-19 | — | — | EP | disclosed |
| EP-1166799-A1 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-02 | — | — | EP | disclosed |
| EP-1166798-A1 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use | Schering Aktiengesellschaft (DE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001097850-A2 | COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II) | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055006-A1 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use | TEK, TIE1, KDR | KDR 3/4885FLT1 4/4885PDGFRB 10/4885 |
| US-20070059359-A1 | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof | PTPN4, PTPN14, PTPN12 | KDR 3882/4885FLT1 3473/4885PDGFRB 3652/4885 |
| US-20040147449-A1 | Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use (II) | TEK, TIE1, KDR | KDR 3/4885FLT1 4/4885PDGFRB 10/4885 |
| US-20060275365-A1 | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof | PTP4A1, DPP4, PTP4A2 | KDR 3484/4885FLT1 3311/4885PDGFRB 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.